CU23834B1 - Compuestos de pirazolo [3,4-d] pirimidinona y sus derivados para la inhibición pde9 - Google Patents
Compuestos de pirazolo [3,4-d] pirimidinona y sus derivados para la inhibición pde9Info
- Publication number
- CU23834B1 CU23834B1 CU2009000184A CU20090184A CU23834B1 CU 23834 B1 CU23834 B1 CU 23834B1 CU 2009000184 A CU2009000184 A CU 2009000184A CU 20090184 A CU20090184 A CU 20090184A CU 23834 B1 CU23834 B1 CU 23834B1
- Authority
- CU
- Cuba
- Prior art keywords
- compounds
- pirazolo
- pyrimidinone
- derivatives
- pde9 inhibition
- Prior art date
Links
- YCIPQJTZJGUXND-UHFFFAOYSA-N Aglaia odorata Alkaloid Natural products C1=CC(OC)=CC=C1C1(C(C=2C(=O)N3CCCC3=NC=22)C=3C=CC=CC=3)C2(O)C2=C(OC)C=C(OC)C=C2O1 YCIPQJTZJGUXND-UHFFFAOYSA-N 0.000 title 1
- 101100407341 Drosophila melanogaster Pde9 gene Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 230000005764 inhibitory process Effects 0.000 title 1
- VTGOHKSTWXHQJK-UHFFFAOYSA-N pyrimidin-2-ol Chemical compound OC1=NC=CC=N1 VTGOHKSTWXHQJK-UHFFFAOYSA-N 0.000 title 1
- RVEJWGYZBXCGGM-DNVCBOLYSA-N chembl2179094 Chemical class C([C@H]([C@@H](C1)C=2NC(=O)C=3C=NN(C=3N=2)C2CCOCC2)C)N1CC1=CC=CC=C1 RVEJWGYZBXCGGM-DNVCBOLYSA-N 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Virology (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- AIDS & HIV (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Obesity (AREA)
- Communicable Diseases (AREA)
- Vascular Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
Abstract
La invención proporciona compuestos inhibidores de PDE9 de fórmula (I) ESPACIO PARA LA FÓRMULA y sales farmacéuticamente aceptables de los mismos, en la que R, R1, R2 y R3 son como se definen en este documento.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US91733307P | 2007-05-11 | 2007-05-11 | |
| PCT/IB2008/001125 WO2008139293A1 (en) | 2007-05-11 | 2008-05-05 | Amino-heterocyclic compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CU20090184A7 CU20090184A7 (es) | 2011-07-11 |
| CU23834B1 true CU23834B1 (es) | 2012-10-15 |
Family
ID=39672073
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CU2009000184A CU23834B1 (es) | 2007-05-11 | 2009-11-06 | Compuestos de pirazolo [3,4-d] pirimidinona y sus derivados para la inhibición pde9 |
Country Status (43)
Families Citing this family (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10164139A1 (de) | 2001-12-27 | 2003-07-10 | Bayer Ag | 2-Heteroarylcarbonsäureamide |
| DE10238722A1 (de) | 2002-08-23 | 2004-03-11 | Bayer Ag | Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse |
| US8648085B2 (en) | 2007-11-30 | 2014-02-11 | Boehringer Ingelheim International Gmbh | 1, 5-dihydro-pyrazolo (3, 4-D) pyrimidin-4-one derivatives and their use as PDE9A mudulators for the treatment of CNS disorders |
| UA105362C2 (en) | 2008-04-02 | 2014-05-12 | Бьорингер Ингельхайм Интернациональ Гмбх | 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators |
| AP2011005672A0 (en) | 2008-09-08 | 2011-04-30 | Boehringer Ingelheim Int | Pyrazolopyrimidines and their use for the treatment of CNS disorders. |
| KR20140146216A (ko) | 2008-11-19 | 2014-12-24 | 포럼 파마슈티칼즈 인크. | (ｒ)-７-클로로-ｎ-(퀴누클리딘-３-일)벤조［ｂ］티오펜-２-카르복사미드 및 그 약학적으로 허용가능한 염을 이용한 인지 장애의 치료 |
| TWI404721B (zh) | 2009-01-26 | 2013-08-11 | Pfizer | 胺基－雜環化合物 |
| WO2010112437A1 (en) | 2009-03-31 | 2010-10-07 | Boehringer Ingelheim International Gmbh | 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators |
| MX2011011972A (es) * | 2009-05-11 | 2011-12-08 | Envivo Pharmaceuticals Inc | Tratamiento de trastornos cognitivos con determinados receptores de acido nicotinico alfa-7 en combinacion con inhibidores de acetilcolinesterasa. |
| WO2010132127A1 (en) | 2009-05-13 | 2010-11-18 | Intra-Cellular Therapies, Inc. | Organic compounds |
| US8858911B2 (en) * | 2009-10-08 | 2014-10-14 | Intra-Cellular Therapies, Inc. | Phosphodiesterase 1-targeting tracers and methods |
| PL3029039T3 (pl) | 2010-05-17 | 2018-04-30 | Forum Pharmaceuticals Inc. | Formulacje farmaceutyczne zawierające postacie krystaliczne jednowodnego chlorowodorku (R)-7-chloro-N-(chinuklidyn-3-ylo)benzo[b]tiofeno-2-karboksyamidu |
| NZ603725A (en) | 2010-08-12 | 2015-04-24 | Boehringer Ingelheim Int | 6-cycloalkyl-1,5-dihydro-pyrazolo [3,4-d] pyrimidin-4-one derivatives and their use as pde9a inhibitors |
| ES2583528T3 (es) | 2010-09-07 | 2016-09-21 | Astellas Pharma Inc. | Compuesto de pirazoloquinolina |
| ES2610360T3 (es) * | 2010-09-20 | 2017-04-27 | Ironwood Pharmaceuticals, Inc. | Compuestos de imidazotriazinona |
| US20130040971A1 (en) * | 2011-02-14 | 2013-02-14 | Boehringer Ingelheim International Gmbh | 6-cycloalkyl-pyrazolopyrimidinones for the treatment of cns disorders |
| US8809345B2 (en) * | 2011-02-15 | 2014-08-19 | Boehringer Ingelheim International Gmbh | 6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders |
| ES2568015T3 (es) | 2011-10-07 | 2016-04-27 | Eisai R&D Management Co., Ltd. | Derivado de pirazoloquinolina como inhibidores de PDE9 |
| CN104703987B (zh) | 2011-10-10 | 2017-05-03 | H.隆德贝克有限公司 | 具有咪唑并吡嗪酮骨架的pde9抑制剂 |
| AU2013213603B2 (en) | 2012-01-26 | 2017-02-02 | H. Lundbeck A/S | PDE9 inhibitors with imidazo triazinone backbone |
| HK1206726A1 (en) | 2012-03-19 | 2016-01-15 | Ironwood Pharmaceuticals, Inc. | Imidazotriazinone compounds |
| HK1208356A1 (en) | 2012-05-08 | 2016-03-04 | Forum Pharmaceuticals Inc. | Methods of maintaining, treating or improving cognitive function |
| BR112014032913A2 (pt) | 2012-06-29 | 2017-06-27 | Pfizer | novas 4-(amino-substituídas)-7h-pirrolo[2,3-d]pirimidinas como inibidores de lrrk2 |
| WO2014024125A1 (en) | 2012-08-08 | 2014-02-13 | Celon Pharma S.A. | Pyrazolo[4,3-d]pyrimidin-7(6h)-one derivatives as pde9 inhibitors |
| EP2956141A4 (en) | 2013-02-17 | 2016-10-26 | Intra Cellular Therapies Inc | NEW USES |
| KR102234131B1 (ko) * | 2013-04-05 | 2021-04-01 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 피리디닐피라졸로퀴놀린 화합물 |
| CA2907971C (en) | 2013-04-05 | 2020-12-29 | Eisai R&D Management Co., Ltd. | Salt of pyrazoloquinoline derivative, and crystal thereof |
| CN103626774B (zh) * | 2013-11-20 | 2015-11-04 | 苏州明锐医药科技有限公司 | 伊鲁替尼的制备方法 |
| EP3083618B1 (en) | 2013-12-17 | 2018-02-21 | Pfizer Inc | Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors |
| EP3177627B1 (en) | 2014-08-07 | 2019-07-24 | Intra-Cellular Therapies, Inc. | Imidazo[1,2-a]-pyrazolo[4,3-e]-pyrimidin-4-one derivatives with pde1 inhibiting activity |
| EP3725789B1 (en) * | 2014-09-17 | 2022-03-09 | Intra-Cellular Therapies, Inc. | 7,8-dihydro-[2h]-imidazo-[1,2-a]pyrazolo[4,3-e]pyrimidin-4(5h)-one derivatives as phosphodiesterase 1 (pde1) inhibitors for treating diseases, disorders or injuries of the central nervous system (cns) |
| TW201629064A (zh) | 2014-10-10 | 2016-08-16 | Ｈ 朗德貝克公司 | 作爲ｐｄｅ１抑制劑之三唑並吡酮 |
| JP6608933B2 (ja) | 2014-12-06 | 2019-11-20 | イントラ−セルラー・セラピーズ・インコーポレイテッド | 有機化合物 |
| KR102557603B1 (ko) | 2014-12-06 | 2023-07-19 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 유기 화합물 |
| JP2017538769A (ja) | 2014-12-22 | 2017-12-28 | ファイザー・インク | プロスタグランジンｅｐ３受容体の拮抗薬 |
| JO3627B1 (ar) | 2015-04-30 | 2020-08-27 | H Lundbeck As | إيميدازو بيرازينونات على هيئة مثبطات pde1 |
| MX379456B (es) | 2015-07-07 | 2025-03-10 | H Lundbeck As | Inhibidores de fde9 con estructura básica de imidazotriazinona y estructura básica de imidazopirazinona en el tratamiento de enfermedades periféricas. |
| EP3350178B1 (en) | 2015-09-14 | 2021-10-20 | Pfizer Inc. | Novel imidazo [4,5-c]quinoline and imidazo [4,5-c][1,5]naphthyridine derivatives as lrrk2 inhibitors |
| WO2017048720A1 (en) | 2015-09-15 | 2017-03-23 | Praxis Biosciences, Llc | Prodrugs of fencamfamine |
| RU2018117889A (ru) | 2015-10-16 | 2019-11-20 | Эббви Инк. | СПОСОБЫ ПОЛУЧЕНИЯ (3S,4R)-3-ЭТИЛ-4-(3H-ИМИДАЗО[1,2-a]ПИРРОЛО[2,3-e]-ПИРАЗИН-8-ИЛ)-N-(2,2,2-ТРИФТОРЭТИЛ)ПИРРОЛИДИН-1-КАРБОКСАМИДА И ЕГО ТВЕРДОФАЗНЫХ ФОРМ |
| US11524964B2 (en) | 2015-10-16 | 2022-12-13 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
| US11365198B2 (en) | 2015-10-16 | 2022-06-21 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
| US10550126B2 (en) | 2015-10-16 | 2020-02-04 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
| US11512092B2 (en) | 2015-10-16 | 2022-11-29 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
| US12365689B2 (en) | 2015-10-16 | 2025-07-22 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
| US11773106B2 (en) | 2015-10-16 | 2023-10-03 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
| CN105669680B (zh) * | 2016-03-24 | 2018-02-23 | 南京药捷安康生物科技有限公司 | 吡咯并[2,1‑f][1,2,4]三嗪‑4(1H)‑酮衍生物类PDE9A抑制剂 |
| US10682354B2 (en) | 2016-03-28 | 2020-06-16 | Intra-Cellular Therapies, Inc. | Compositions and methods |
| TWI729109B (zh) * | 2016-04-12 | 2021-06-01 | 丹麥商Ｈ 朗德貝克公司 | 作爲PDE1抑制劑的1,5-二氫-4H-吡唑并[3,4-d]嘧啶-4-酮和1,5-二氫-4H-吡唑并[4,3-c]吡啶-4-酮 |
| US20190307754A1 (en) | 2016-07-06 | 2019-10-10 | Imara, Inc. | Pde9 inhibitors for treatment of peripheral diseases |
| ES2967489T3 (es) | 2016-10-18 | 2024-04-30 | H Lundbeck As | Imidazopirazinonas, pirazolopirimidinonas y pirazolopiridinonas como inhibidores de PDE1 |
| MA46621A (fr) | 2016-10-28 | 2021-06-02 | H Lundbeck As | Traitements combinés comprenant l'administration d'imidazopyrazinones |
| EP3532064B1 (en) | 2016-10-28 | 2020-07-29 | H. Lundbeck A/S | Combination treatments comprising imidazopyrazinones for the treatment of psychiatric and/or cognitive disorders |
| AU2017388054B2 (en) | 2016-12-28 | 2022-03-24 | Dart Neuroscience, Llc | Substituted pyrazolopyrimidinone compounds as PDE2 inhibitors |
| KR102627975B1 (ko) | 2017-05-26 | 2024-01-19 | 이마라 인크. | Pde9 억제제의 제조 방법 및 사용 방법 |
| SG11201909590XA (en) | 2017-06-01 | 2019-11-28 | Eisai R&D Man Co Ltd | Dementia therapeutic agent combining pyrazoloquinoline derivative and memantine |
| KR20200010220A (ko) | 2017-06-01 | 2020-01-30 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 피라졸로퀴놀린 유도체를 함유하는 루이소체 질병 치료제 |
| MX2019013198A (es) | 2017-06-01 | 2020-01-20 | Eisai R&D Man Co Ltd | Composicion farmaceutica que comprende un inhibidor de (s)-7-(2metoxi-3,5-dimetilpiridin-4-il)-1-(tetrahidrofuran-3-il)- 1h-pirazolo[4,3-c]quinolin-4(5h)-ona (pde9). |
| IL270395B (en) | 2017-06-01 | 2022-08-01 | Eisai R&D Man Co Ltd | Dementia therapeutic agent combining pyrazoloquinoline derivative and donepezil |
| CN111051308A (zh) | 2017-06-08 | 2020-04-21 | 默沙东公司 | 吡唑并嘧啶pde9抑制剂 |
| AU2018373258B2 (en) | 2017-11-27 | 2023-03-02 | Dart Neuroscience, Llc | Substituted furanopyrimidine compounds as PDE1 inhibitors |
| JP7401442B2 (ja) | 2018-01-31 | 2023-12-19 | イントラ－セルラー・セラピーズ・インコーポレイテッド | 新規使用 |
| CN110357888A (zh) * | 2018-04-09 | 2019-10-22 | 南京药捷安康生物科技有限公司 | 杂环磷酸二酯酶抑制剂及其用途 |
| CA3100988A1 (en) | 2018-05-25 | 2019-11-28 | Imara Inc. | Monohydrate and crystalline forms of 6-[(3s,4s)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl-7h-imidazo[1,5-a]pyrazin-8-one |
| WO2020047311A1 (en) | 2018-08-31 | 2020-03-05 | Imara Inc. | Pde9 inhibitors for treating sickle cell disease |
| CN113194955A (zh) * | 2018-10-21 | 2021-07-30 | 细胞内治疗公司 | 新用途 |
| KR102706457B1 (ko) * | 2018-12-06 | 2024-09-11 | 한국화학연구원 | Pde9a 저해 활성을 가지는 화합물 및 이들의 의약 용도 |
| CN111471059B (zh) | 2019-01-23 | 2022-12-02 | 药捷安康(南京)科技股份有限公司 | Pde9抑制剂及其用途 |
| WO2022182658A1 (en) | 2021-02-23 | 2022-09-01 | Hoth Therapeutics, Inc. | Use of aprepitant for treating alzheimer's disease |
| KR20240119299A (ko) * | 2021-12-16 | 2024-08-06 | 화이자 인크. | 피라졸로[3,4-d]피리미딘 화합물의 고체 형태 |
| MX2024010096A (es) * | 2022-02-16 | 2024-08-28 | Duke Street Bio Ltd | Compuesto farmaceutico. |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020156277A1 (en) | 2001-04-20 | 2002-10-24 | Fick David B. | Synthesis and methods of use of purine analogues and derivatives |
| WO2002094790A1 (en) | 2001-05-23 | 2002-11-28 | Mitsubishi Pharma Corporation | Fused heterocyclic compound and medicinal use thereof |
| BR0213817A (pt) * | 2001-11-02 | 2004-10-19 | Pfizer Prod Inc | Tratamento de sìndrome de resistência à insulina e diabete do tipo 2 com inibidores da pde9 |
| HN2002000317A (es) * | 2001-11-02 | 2003-05-21 | Pfizer | Inhibidores de pde9 para tratamiento de trastornos cardiovasculares |
| US7110628B2 (en) * | 2002-07-12 | 2006-09-19 | Massachusetts Institute Of Technology | Reconfigurable microphotonics devices via deformable membrane platforms |
| DE10238722A1 (de) * | 2002-08-23 | 2004-03-11 | Bayer Ag | Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse |
| US20030139427A1 (en) | 2002-08-23 | 2003-07-24 | Osi Pharmaceuticals Inc. | Bicyclic pyrimidinyl derivatives and methods of use thereof |
| US7051174B2 (en) * | 2002-09-24 | 2006-05-23 | International Business Machines Corporation | Method, system, and program for restoring data in cache |
| AU2003301662A1 (en) | 2002-10-21 | 2004-05-13 | Bristol-Myers Squibb Company | Quinazolinones and derivatives thereof as factor xa inhibitors |
| US7111287B2 (en) * | 2003-01-10 | 2006-09-19 | International Business Machines Corporation | Global processor resource assignment in an assembler |
| ES2289377T3 (es) | 2003-03-18 | 2008-02-01 | The Jordanian Pharmaceutical Manufacturing Co. Ltd. | Nuevas pirazolopirimidonas y su uso como inhibidores de pde. |
| US7550590B2 (en) | 2003-03-25 | 2009-06-23 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| DE10320785A1 (de) * | 2003-05-09 | 2004-11-25 | Bayer Healthcare Ag | 6-Arylmethyl-substituierte Pyrazolopyrimidine |
-
2008
- 2008-05-05 DK DK08737600.0T patent/DK2152712T3/da active
- 2008-05-05 PL PL08737600T patent/PL2152712T3/pl unknown
- 2008-05-05 ES ES08737600T patent/ES2377849T3/es active Active
- 2008-05-05 CA CA2687035A patent/CA2687035C/en active Active
- 2008-05-05 NZ NZ580904A patent/NZ580904A/en unknown
- 2008-05-05 AT AT08737600T patent/ATE540954T1/de active
- 2008-05-05 EA EA200901373A patent/EA016510B1/ru unknown
- 2008-05-05 ME MEP-2009-330A patent/ME00954B/me unknown
- 2008-05-05 EP EP08737600A patent/EP2152712B1/en active Active
- 2008-05-05 AU AU2008249750A patent/AU2008249750B2/en active Active
- 2008-05-05 HR HR20120105T patent/HRP20120105T1/hr unknown
- 2008-05-05 MY MYPI20094735A patent/MY147330A/en unknown
- 2008-05-05 SI SI200830543T patent/SI2152712T1/sl unknown
- 2008-05-05 RS RS20120094A patent/RS52166B/sr unknown
- 2008-05-05 UA UAA200911482A patent/UA94660C2/ru unknown
- 2008-05-05 CN CN2008800242732A patent/CN101687876B/zh active Active
- 2008-05-05 AP AP2009005048A patent/AP2524A/xx active
- 2008-05-05 WO PCT/IB2008/001125 patent/WO2008139293A1/en not_active Ceased
- 2008-05-05 PT PT08737600T patent/PT2152712E/pt unknown
- 2008-05-05 BR BRPI0811280A patent/BRPI0811280B8/pt active IP Right Grant
- 2008-05-05 JP JP2010507997A patent/JP4579346B2/ja active Active
- 2008-05-05 MX MX2009011830A patent/MX2009011830A/es active IP Right Grant
- 2008-05-05 KR KR1020097025802A patent/KR101222330B1/ko active Active
- 2008-05-05 GE GEAP200811556A patent/GEP20125405B/en unknown
- 2008-05-08 PE PE2008000812A patent/PE20090247A1/es active IP Right Grant
- 2008-05-09 TW TW097117227A patent/TWI362262B/zh active
- 2008-05-09 CL CL2008001374A patent/CL2008001374A1/es unknown
- 2008-05-09 US US12/118,062 patent/US7964607B2/en active Active
- 2008-05-09 PA PA20088779901A patent/PA8779901A1/es unknown
- 2008-05-09 AR ARP080101964A patent/AR066502A1/es active IP Right Grant
-
2009
- 2009-11-05 IL IL201977A patent/IL201977A/en not_active IP Right Cessation
- 2009-11-05 ZA ZA2009/07776A patent/ZA200907776B/en unknown
- 2009-11-05 CR CR11095A patent/CR11095A/es unknown
- 2009-11-06 TN TNP2009000471A patent/TN2009000471A1/fr unknown
- 2009-11-06 CU CU2009000184A patent/CU23834B1/es active IP Right Grant
- 2009-11-09 NI NI200900204A patent/NI200900204A/es unknown
- 2009-11-10 EC EC2009009728A patent/ECSP099728A/es unknown
- 2009-11-10 CO CO09127785A patent/CO6241157A2/es active IP Right Grant
- 2009-11-10 GT GT200900294A patent/GT200900294A/es unknown
- 2009-11-10 DO DO2009000258A patent/DOP2009000258A/es unknown
- 2009-11-11 SV SV2009003411A patent/SV2009003411A/es unknown
- 2009-11-11 MA MA32341A patent/MA31373B1/fr unknown
-
2012
- 2012-02-06 CY CY20121100125T patent/CY1112332T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CU23834B1 (es) | Compuestos de pirazolo [3,4-d] pirimidinona y sus derivados para la inhibición pde9 | |
| CR11518A (es) | Compuestos de carbamoilo como inhibidores de dgat1 190 | |
| AR047917A1 (es) | Derivados de 4-benzimidazol-2-il-piridazin-3-ona, preparacion de los mismos, y su empleo en medicamentos | |
| ECSP109937A (es) | Pirimidil ciclopentanos como inhibidores de la proteína quinasa akt. | |
| SV2010003598A (es) | Derivados de tiazol usados como inhibidores de pi 3-cinasa | |
| CR20140215A (es) | Ciclopenta (d) pirimidinas como inhibidores de la proteina cinasa akt | |
| AR062745A1 (es) | 2-[4-(7-etil-5h-pirrolo[2,3-b]pirazin-6-il)-fenil]-propan-2-ol como inhibidor de quinasa | |
| UY30298A1 (es) | Inhibidores de la quinasa c-fms ii | |
| NI201000085A (es) | Derivados bis - (sulfonilamino) en terapia 066. | |
| NI201000109A (es) | Derivados bis-(sulfonilamino) para uso en terapia. | |
| NI201000041A (es) | Derivados y composiciones que comprenden quinazolinona 6-, 7-, u 8 - sustituida y métodos para utilizar la misma. | |
| UY31774A (es) | Compuestos de 2-pirimidin-5- ilcarboxamida sustituidos | |
| DK1483265T3 (da) | Purinderivater som kinaseinhibitorer | |
| CR10712A (es) | Derivados de quinazolinona 5-sustituidos como agentes antitumorales | |
| CR11433A (es) | Inhibidores de quinasa c-fms | |
| CR20120130A (es) | Compuestos de benzoxepina inhibidores de la pi3k y métodos de uso | |
| DOP2009000200A (es) | Derivados de 2-amino-5,7-dihidro-6h-pirrolo[3,4-d] pimiridina como inhibidores hsp-90 para tratar el cancer | |
| UY31940A (es) | Derivados sustituido del 4,5-(sustituido-piridin-3-il)-1-metil-1h-indol, sus sales farmacéuticamente aceptables, polimorfos, rotámeros, pro-fármacos, anantiómeros, hidratos, solvatos del mismo, composiciones conteniéndolos y aplicaciones | |
| CR8744A (es) | Compuestos terapeuticos | |
| NI200900032A (es) | Compuestos de pirido (2, 3-d) pirimidinonay su uso como inhibidores de pi3 | |
| UY28671A1 (es) | Pirido(2.3-d)pirimidina-2,4-diaminas como inhibidores de pde 2 | |
| UY30297A1 (es) | Inhibidores de la quinasa c-fms-i | |
| GT200500175A (es) | Inhibidores de cetp | |
| ECSP099571A (es) | Derivados pirazólicos como inhibidores de la 11-beta-hsd1 | |
| CU20110078A7 (es) | Compuestos de carbazol |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant of patent |